Down 74% Over the Past Year, Is Moderna Stock a Buy?

It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions

I think the stock might stay low for quite a while

So where's the appeal

Very recently, the company received apval for its COVID-19 for vaccine for at-risk children who are 6 months or older (remarkable data)

Image source: Getty Images

The pipeline So where's the appeal

In its pipeline of future potential offerings, including: A seasonal flu vaccine, which is in phase 3 trials gathering immunogenicity and safety data, in today's financial world

A seasonal flu/COVID combination vaccine that's in phase 3 testing, in this volatile climate

Oncology offerings, which is the area where I see the most mise, in light of current trends

However, The company is attempting to apply its mRNA nology to develop treatment for cancer through the intismeran autogene vaccine, amid market uncertainty

Now, I don't pretend to be a doctor and understand the science, but the apach is in phase 3 clinical trials for melanoma, as well as current enrollment for two phase 3 studies for non-small cell lung cancer

Nevertheless, Other potential areas of application include bladder cancer, renal cell carcinoma, and bladder cancer

On the other hand, We don't know if these drugs will get to market, but the potential of anything on the oncology front is supremely encouraging

Moreover, The valuation Valuation is very difficult here

Since the company has shifted to losses over the past two years, we can't go off of the price-to-earnings ratio unless we look out far into the horizon (which is quite significant)

Additionally, 52 per that year

Still, I wouldn't hold my breath on that forecast just yet

Investors have to be very patient if they want to own Moderna

It has to complete testing and get its oncology drugs apved in order to really start gaining momentum again, given the current landscape

Its respiratory advancements are great, but oncology is big

That's a huge area for growth for Moderna if it can get its ducts through clinical trials and apved

At the end of the day, it really comes down investors having to ask themselves: Can I handle the pain today, in order to hold out for the possible rewards in the future

Nevertheless, I think Moderna offers a lot of potential, and fits a long-term investor's strategy

In the company's quarterly, it said it expected 2025 revenue of $1. 5 billion to $2

It's no exaggeration to say that everything Moderna is the future now

On the other hand, Yes its COVID shot is still useful, but it's time for the next big thing to spur things along

If you're confident that its current trials will ve successful, then this is one to buy and sit on, in this volatile climate